Sensorion SA Profile Avatar - Palmy Investing

Sensorion SA

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin def…

Biotechnology
FR, Montpellier [HQ]
ALSEN.PA/Financial Reporting

Income Statements

13 Sheets · Starting from 2011
In Million EUR. Margins, Growth Rates In %
Metric 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Revenue
- - - - - - - - - - - - 1.00 2.00 2.00 2.00 4.00 4.00 4.00
EPS
-0.15 -0.30 -0.50 -0.94 -1.00 -1.09 -1.34 -1.08 -0.65 -0.15 -0.19 -0.29 -0.17
Profit
- - - - - - - - -3.00 -6.00 1.00 1.00 2.00 1.00 3.00 4.00 3.00
Pre Tax
- - - - -1.00 -3.00 -5.00 -9.00 -9.00 -12.00 -14.00 -10.00 -18.00 -27.00 -26.00
ETR
24.19 -1.47 -9.48 -7.05 -19.96 -18.32 19.47 17.98 16.88 17.06 16.57 14.33 16.15
Net
- - - - -1.00 -3.00 -4.00 -7.00 -9.00 -12.00 -12.00 -8.00 -15.00 -23.00 -22.00
EBITDA
- - - - -1.00 -2.00 -5.00 -8.00 -9.00 -11.00 -13.00 -10.00 -18.00 -27.00 -27.00
Operating Income
- - - - -1.00 -2.00 -5.00 -9.00 -9.00 -12.00 -13.00 -11.00 -19.00 -28.00 -27.00
Interest Income
- - - - - - - - - - - - - - - - - - - - - - - - - -
Loss
- - -1.00 -1.00 -3.00 -5.00 -9.00 -11.00 -14.00 -13.00 -11.00 -19.00 -28.00 -27.00
Cost of Revenue
- - - - - - - - -3.00 -6.00 - - - - - - - - - - - - - -
Operating Expenses
- - -1.00 -1.00 -3.00 -1.00 -2.00 -11.00 -14.00 -13.00 -10.00 -18.00 -27.00 -27.00
Depreciation and Amortization
- - - - - - - - - - - - - - - - - - - - - - - - - -
Interest Expenses
- - - - - - - - - - - - - - - - -1.00 - - - - - - - -
Other Expenses
- - - - - - - - - - - - - - - - -1.00 - - -1.00 -1.00 -1.00
WA Shares Outstanding
3.00 3.00 3.00 3.00 4.00 6.00 7.00 11.00 18.00 60.00 79.00 79.00 133.00
End of ALSEN.PA's Analysis
CIK: - CUSIP: F8312Z102 ISIN: FR0012596468 LEI: - UEI: -
Secondary Listings
ALSEN.PA has no secondary listings inside our databases.